Etoposide , 98% , 33419-42-0

Synonym(s):
4′-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-β-D-glucopyranoside);Etoposide;VP16;VP-16

CAS NO.：33419-42-0

Empirical Formula: C29H32O13

Molecular Weight: 588.56

MDL number: MFCD00869325

EINECS: 251-509-1

PRODUCT Properties

• Melting point: 236-251 °C (lit.)
• Boiling point: 563.9°C (rough estimate)
• alpha: D20 -110.5° (c = 0.6 in chloroform)
• Density: 1.2966 (rough estimate)
• refractive index: -110.5 ° (C=0.6, CHCl3)
• storage temp.: 2-8°C
• solubility: DMSO: 30 mg/mL
• form: powder
• pka: 9.8(at 25℃)
• color: white
• Water Solubility: Insoluble in water.
• Merck: 14,3886
• BCS Class: 4
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months

Description and Uses

Etoposide is a plant alkaloid and an inhibitor of topoisomerase II (IC₅₀ = 60.3 μM). It inhibits proliferation of a variety of adenocarcinoma cells (IC₅₀s = 0.005-12,200 μM) and human umbilical vein endothelial (HUVEC) cells (IC₅₀ = 0.249 μM). It reduces tumor growth in an Ma human embryonal carcinoma mouse xenograft model when administered at a dose of 25 mg/kg, an effect that is enhanced by concomitant administration of the immunosuppressant cyclosporin A . Etoposide also inhibits nuclear receptor coactivator 3 (IC₅₀ = 2.48 μM). Formulations containing etoposide have been used in combination therapy in the treatment of cancer.

Etoposide is used for germinogenic tumors, ovarian, stomach, and lung cancer, Hodgkin’s disease, and non-Hodgkin’s lymphoma for both monotherapy and in combination therapy.

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Danger
• Hazard statements: H302-H350-H361d-H412
• Precautionary statements: P201-P280-P301+P312+P330-P308+P313
• Hazard Codes: T,Xi
• Risk Statements: 45-22-36/37/38
• Safety Statements: 53-45-36/37-26
• RIDADR: 3249
• WGK Germany: 3
• RTECS: KC0190000
• HazardClass: 6.1(a)
• PackingGroup: II
• HS Code: 29389090
• Toxicity: LD50 oral in rabbit: 147mg/kg